Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study.

Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.

[1]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[2]  M. Armstrong,et al.  Severe imported falciparum malaria among adults requiring intensive care: a retrospective study at the hospital for tropical diseases, London , 2013, BMC Infectious Diseases.

[3]  R. Davidson,et al.  Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre , 2012, Pathogens and global health.

[4]  T. Rolling,et al.  Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia , 2012, Malaria Journal.

[5]  P. V. van Genderen,et al.  Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium , 2012, Malaria Journal.

[6]  N. Suttorp,et al.  Intravenous Artesunate for Severe Malaria in Travelers, Europe , 2011, Emerging infectious diseases.

[7]  Kamolrat Silamut,et al.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.

[8]  P. Gastmeier,et al.  Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database , 2010, Intensive Care Medicine.

[9]  Arjen Dondorp,et al.  Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.

[10]  R. López-Vélez,et al.  Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.